Shining the Spotlight on Multiple Daily Insulin Therapy: Real-World Evidence of the InPen Smart Insulin Pen
Authors' conclusion
This analysis, integrating data from a smart insulin pen and CGM, provides insights into the impact of dosing behavior on glycemic outcomes and informs counseling strategies for the diabetes care team, through technologically advanced insulin management for those using MDI therapy.
Study context
- Population
- Persons with T1D and T2D using the InPen smart insulin pen paired with continuous glucose monitoring (CGM) (InPen system), January 01, 2020, to December 31, 20213,793 T1D, 552 T2D, 808 unidentified
- Outcome
- Dosing behaviour and glycemia
Methodological detailsreal-world data
- Real-world data
Main finding
As reported in the abstract
- Overall and T1D populations: dosing frequency of ≥3 doses per day and missed dose frequency of <20% associated with improved glycemia
- Adults with T2D: missing <20% of doses was the significant factor determining improved glycemia
Observational data: associations, not effects.
Original publication
Shining the Spotlight on Multiple Daily Insulin Therapy: Real-World Evidence of the InPen Smart Insulin Pen. Diabetes Technol Ther. Published 29 November 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →